Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial-Reference-Cited by-同舟云学术

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial

Published:2012-06-26 Issue:2 Volume:107 Page:230-233
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Sestak I,Kealy R,Nikoloff M,Fontecha M,Forbes J F,Howell A,Cuzick J

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2012278.pdf

Reference25 articles.

1. Azoulay L, Dell’Aniello S, Huiart L, du Fort GG, Suissa S (2011) Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat 126 (3): 695–703

2. Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P, Travaglini R, Muraca MG, Rotmensz N, Veronesi U, Decensi AU (2006) Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 24 (22): 3708–3709

3. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80 (1): 61–74

4. Brauch H, Jordan VC (2009) Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the ‘personalised' approach? Eur J Cancer 45 (13): 2274–2283

5. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T, IBIS investigators (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 (9336): 817–824

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SIGNIFICANCE OF CYP2D6 GENE POLYMORPHISM FOR DETERMINING THE RISK OF BREAST CANCER;Proceedings of the 1st International Congress "The Latest Achievements of Medicine, Healthcare, and Health-Saving Technologies";2023-02-16

2. Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions;Pharmacogenomics and Personalized Medicine;2021-02

3. Recent advances in the personalized treatment of estrogen receptor-positive breast cancer with tamoxifen: a focus on pharmacogenomics;Expert Opinion on Drug Metabolism & Toxicology;2020-12-29

4. Genetic Variation and Hot Flashes: A Systematic Review;The Journal of Clinical Endocrinology & Metabolism;2020-08-14

5. Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?;The Breast;2019-08